Over many years, definitive diagnosis of AD could only be made by the “gold standard” of postmortem neuropathological examination, using a combination of CERAD score for neuritic plaques containing amyloid beta (Aβ) (16) together with Braak staging of NFT consisting of abnormally hyperphosphorylated tau (17). The gene discussed is MAPT; the disease is Alzheimer disease.